Semaglutide vs Liraglutide: Ozempic vs Saxenda for Weight Loss

Semaglutide and liraglutide are both GLP-1 receptor agonists—peptide-based medications that mimic glucagon-like peptide-1, a gut hormone that regulates appetite, insulin secretion, and gastric emptying. They represent two generations of the same drug class, and choosing between them involves real trade-offs in efficacy, side effects, dosing convenience, and cost.

This comparison focuses specifically on their use for weight management: semaglutide (Ozempic, Wegovy) versus liraglutide (Victoza, Saxenda).

How GLP-1 Receptor Agonists Work

GLP-1 is a peptide hormone secreted by L-cells in the intestinal lining in response to food. It has several metabolic effects:

• Stimulates insulin secretion in a glucose-dependent manner (reduces when blood glucose is normal, thus low hypoglycemia risk)
• Inhibits glucagon secretion, reducing hepatic glucose production
• Slows gastric emptying, causing food to move through the stomach more slowly and prolonging satiety
• Acts on the hypothalamus to reduce appetite and food intake
• Reduces reward-driven eating via action on dopaminergic pathways

The limitation of native GLP-1 is a half-life of 2 minutes—it is rapidly degraded by DPP-4 enzymes. Both semaglutide and liraglutide are engineered to resist DPP-4 degradation, but they achieve this differently and with different resulting half-lives.

Semaglutide (Ozempic/Wegovy)

Semaglutide was developed by Novo Nordisk and approved by the FDA for type 2 diabetes (Ozempic, 2017) and obesity treatment (Wegovy, 2021). Its half-life is approximately 165–184 hours (about one week), achieved through:

• Fatty acid chain modification that facilitates albumin binding
• Substitution of alanine at position 8 with Aib (alpha-aminoisobutyric acid) to prevent DPP-4 cleavage

This long half-life is what makes once-weekly dosing viable. Semaglutide reaches steady-state plasma levels after 4–5 weeks of weekly dosing.

Wegovy dosing for weight management:

• Starting dose: 0.25 mg weekly for 4 weeks
• Escalate by 0.25 mg every 4 weeks
• Target dose: 2.4 mg weekly (maintenance)
• Total escalation period: approximately 16 weeks

Weight loss data from the STEP trials: The STEP 1 trial (2021, n=1961) found that semaglutide 2.4 mg weekly produced a mean weight loss of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. Approximately 32% of participants lost more than 20% of body weight. These are among the most impressive weight loss outcomes ever recorded in a pharmaceutical trial short of bariatric surgery.

Liraglutide (Victoza/Saxenda)

Liraglutide was also developed by Novo Nordisk and approved for diabetes (Victoza, 2010) and obesity (Saxenda, 2014). Its half-life is approximately 13 hours, requiring once-daily injection. It also uses fatty acid chain modification for albumin binding but with a shorter chain than semaglutide.

Saxenda dosing for weight management:

• Starting dose: 0.6 mg daily for 1 week
• Escalate by 0.6 mg/week
• Target dose: 3.0 mg daily (maintenance)
• Total escalation period: approximately 5 weeks

Weight loss data from the SCALE trial: The SCALE Obesity and Prediabetes trial (2015, n=3731) found that liraglutide 3.0 mg daily produced a mean weight loss of 8.4% of body weight over 56 weeks, compared to 2.8% in the placebo group.

Head-to-Head Comparison

| Factor | Semaglutide (Wegovy) | Liraglutide (Saxenda) | |---|---|---| | Injection frequency | Once weekly | Once daily | | Average weight loss | ~15% body weight | ~8% body weight | | % losing >5% body weight | ~87% | ~63% | | % losing >10% body weight | ~66% | ~33% | | Time to maximum dose | ~16 weeks | ~5 weeks | | Half-life | ~165 hours | ~13 hours | | FDA approval for obesity | Yes (Wegovy) | Yes (Saxenda) | | Typical monthly cost (brand) | $1,000–$1,400 | $900–$1,200 | | GI side effects | Similar profile | Similar profile |

The efficacy difference between semaglutide and liraglutide is clinically significant—not marginal. Semaglutide approximately doubles the average weight loss of liraglutide. This means that for someone with a meaningful amount of weight to lose, semaglutide will typically produce better outcomes even before convenience is factored in.

Side Effect Profiles

Both drugs share the same class-based side effects because they act on the same receptor. The side effects are primarily GI:

• Nausea: Most common, affecting 30–50% of users to varying degrees; typically worst in the first 4–8 weeks and with each dose escalation
• Vomiting: Less common than nausea; more frequent at higher doses
• Diarrhea: Common in the first weeks; usually resolves
• Constipation: Paradoxically also common; gastric slowing can cause delayed transit in some
• Reduced appetite: Intentional effect; can be severe in some users

More serious but less common:

• Pancreatitis: Risk appears elevated vs placebo; absolute risk remains low (~0.3%)
• Gallbladder disease: Rapid weight loss increases gallstone risk with both agents
• Thyroid C-cell tumors: Observed in rodents; black box warning on both drugs; human relevance uncertain
• Hypoglycemia: Low risk when used without insulin or sulfonylureas

Comparing tolerability: Because semaglutide has a much longer half-life, it maintains more stable plasma concentrations. Some patients actually tolerate semaglutide better than liraglutide for this reason—daily peaks and troughs with liraglutide can mean daily nausea fluctuation, while semaglutide's steady-state is more consistent. However, individuals vary considerably.

Daily vs Weekly Injection: Practical Considerations

The weekly vs daily injection distinction matters more for adherence than it might seem. Adherence data for GLP-1 agonists shows:

• Daily injections create more opportunities for missed doses and medication fatigue
• Weekly injections align more easily with once-a-week habit formation
• Long-term adherence rates are higher with weekly dosing in real-world data

For people who are strongly needle-averse, oral semaglutide (Rybelsus, 3/7/14 mg tablets) is FDA-approved for diabetes. Oral semaglutide for obesity (at higher doses) is in clinical trials but not yet approved. There is no oral formulation of liraglutide.

Cost and Insurance Coverage

Both semaglutide and liraglutide are expensive. Brand-name monthly costs are broadly similar at $900–$1,400/month without insurance. Insurance coverage is inconsistent—many plans cover the diabetes indications (Ozempic, Victoza) but deny the obesity indications (Wegovy, Saxenda) despite obesity being a recognized medical condition.

Cost-reducing options:

• Manufacturer savings programs (Novo Nordisk patient assistance): can reduce cost to $25–$99/month with qualifying insurance
• Compounded semaglutide: available through some compounding pharmacies at significantly lower cost; regulatory status has been contested and varies by jurisdiction
• Telehealth platforms: several now offer GLP-1 prescriptions with negotiated pricing

See also: semaglutide vs tirzepatide for how semaglutide compares to the newer dual GLP-1/GIP agonist Mounjaro/Zepbound, and semaglutide vs AOD-9604 for a comparison with a peptide-based fat-loss alternative.

Who Should Consider Each?

Semaglutide is generally preferable when:

• Maximum weight loss is the primary goal
• Weekly dosing convenience matters
• You are willing to go through the longer dose escalation period
• Insurance or cost is not a barrier

Liraglutide may be preferable when:

• Faster dose escalation to therapeutic levels is needed
• You have had prior experience with GLP-1 drugs and know your tolerability
• Cost savings matter (marginally lower cost in some markets)
• You need the diabetes indication specifically covered

Frequently Asked Questions

Q: Is semaglutide better than liraglutide for weight loss? Based on the available clinical trial data, yes—semaglutide at its approved obesity dose (2.4 mg weekly) produces approximately double the weight loss of liraglutide at its approved obesity dose (3.0 mg daily). The difference is clinically meaningful, not marginal.

Q: Can you switch from liraglutide to semaglutide? Yes. Transitioning from liraglutide to semaglutide is done with physician guidance, typically starting semaglutide at the lowest dose and re-escalating. The two drugs do not need to be washed out before switching.

Q: Why does semaglutide cause so much nausea? Nausea is caused by the slowed gastric emptying and direct GLP-1 receptor activation in the brainstem's chemoreceptor trigger zone. Starting at low doses and escalating slowly is the main strategy to minimize nausea. It typically improves significantly after the first 4–8 weeks.

Q: Do these drugs work long-term, or do you regain weight if you stop? Both drugs require continued use to maintain results. The STEP 4 trial found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. These medications manage a chronic condition; they are not a cure.

Q: Is compounded semaglutide as effective as brand-name Wegovy? If the compound is properly formulated and dosed, the semaglutide molecule itself is identical. Quality control varies significantly between compounding pharmacies, making sourcing from accredited pharmacies critical.